Pharmacological interventions for the treatment of depression in chronic obstructive pulmonary disease

Cochrane Database of Systematic Reviews

Volumn 2016, Issue 9, 2016, Pages

  Naqvi, Syeda Shaherbano ^a   Pollok, Justyna ^b,c   van Agteren, Joseph E M ^a,b   Usmani, Zafar A ^a   Carson, Kristin V ^b,c   Smith, Brian J ^a,c   Licinio, Julio ^d  

^a QUEEN ELIZABETH HOSPITAL   (Australia)

^b Centre for Inflammatory Disease Research (CIDR)   (Australia)

^c UNIVERSITY OF ADELAIDE   (Australia)

^d SOUTH AUSTRALIAN HEALTH AND MEDICAL RESEARCH INSTITUTE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; BENZODIAZEPINE DERIVATIVE; MONOAMINE OXIDASE INHIBITOR; NEUROLEPTIC AGENT; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT; TRIPLE REUPTAKE INHIBITOR;

ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL EFFECTIVENESS; COCHRANE LIBRARY; COMORBIDITY ASSESSMENT; DEPRESSION; HUMAN; INTERVENTION STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; RISK ASSESSMENT; SENSITIVITY ANALYSIS; SYSTEMATIC REVIEW;

EID: 84986309330     PISSN: 14651858     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD012346     Document Type: Article

References (68)

1. Abrams TE, Vaughan-Sarrazin M, van der Weg MW. Acute exacerbations of chronic obstructive pulmonary disease and the effect of existing psychiatric comorbidity on subsequent mortality. Psychosomatics 2011;52(5):441-9.
2. Allen NJ, Barres BA. Neuroscience: Glia - more than just brain glue. Nature 2009;457(7230):675-7.
3. Almagro P, Calbo E, Ochoa de Echaguen A, Barreiro B, Quintana S, et al. Mortality after hospitalization for COPD. Chest 2002;121(5):1441-8.
4. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th Edition. Washington DC: American Psychiatric Association, 2000.
5. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 5th Edition. Washington DC: American Psychiatric Publishing, 2013.
6. Atlantis E, Fahey P, Cochrane B, Smith S. Biodirectional associations between clinically relevant depression or anxiety and COPD: a systematic review and meta-analysis. Chest 2013;144(3):766-77.
7. American Thoracic Society. ATS statement: guidelines for the six-minute walk test. American Journal of Respiratory and Critical Care Medicine 2002;166:111-7.
8. Beck AT, Ward CH. An inventory for measuring depression. Archives of General Psychiatry 1961;4:561-71.
9. Bentsen SB, Miaskowski C, Rustoen T. Demographic and clinical characteristics associated with quality of life in patients with chronic obstructive pulmonary disease. Quality of Life Research 2014;23:991-8.
10. Bespalov MM, Saarma M. GDNF family receptor complexes are emerging drug targets. Trends in pharmacological sciences 2007;28(2):68-74.
11. Borg GAV. Psychophysical basis of perceived exertion. Medicine and Science in Sports and Exercise 1982;14(5):377-81.
12. Borson S, McDonald GJ, Gayle T, Deffebach M, Lakshminarayan S, vanTuinen C. Improvement in mood, physical symptoms, and function with nortriptyline for depression in patients with chronic obstructive pulmonary disease. Psychosomatics 1992;33(2):190-201.
13. Butland RJ, Pang J, Gross ER, Woodcock AA, Geddes DM. Two-, six-, and 12-minute walking tests in respiratory disease. British Medical Journal 1982;284(6329):1607-8.
14. Cafarella PA, Effing TW, Usmani ZA, Frith PA. Treatments for anxiety and depression in patients with chronic obstructive pulmonary disease: a literature review. Respirology 2012;17:627-38.
15. Coventry PA, Bower P, Keyworth C, Kenning C, Knopp J, Garrett C, et al. The effect of complex interventions on depression and anxiety in chronic obstructive pulmonary disease: systematic review and meta-analysis. PLoS One 2013;8(4):e60532.
16. Cully JA, Graham DP, Stanley MA, Ferguson CJ, Sharafkhaneh A, Souchek J, et al. Quality of life in patients with chronic obstructive pulmonary disease and comorbid anxiety or depression. Psychosomatics 2006;47(4):312-9.
17. Dalal AA, Shah M, Lunacsek O, Hanania NA. Clinical and economic burden of depression/anxiety in chronic obstructive pulmonary disease patients within a managed care population. COPD: Journal of Chronic Obstructive Pulmonary Disease 2011;8:293-9.
18. de Voogd JN, Wempe JB, Koëter GH, Postema K, van Sonderen E, Ranchor AV, et al. Depressive symptoms as predictors of mortality in patients with COPD. Chest Journal 2009;135(3):619-25.
19. DeJean D, Giacomini M, Vanstone M, Brundisini F. Patient experiences of depression and anxiety with chronic disease: a systematic review and qualitative meta-synthesis. Health Quality Ontario 2013;13(16):1-33.
20. Di Marco F, Verga M, Reggenta M, Maria Casanova F, Santus P, Blasi F, et al. Anxiety and depression in COPD patients: the roles of gender and disease severity. Respiratory Medicine 2006;100(10):1767-74.
21. Dinicola G, Julian L, Gregorich SE, Blan PD, Katz PP. The role of social support in anxiety for persons with COPD. Journal of Psychosomatic Research 2013;74(2):110-5.
22. Eiser N, Harte R, Spiros K, Phillips C, Isaac MT. Effect of treating depression on quality-of-life and exercise tolerance in severe COPD. COPD: Journal of Chronic Obstructive Pulmonary Disease 2005;2(2):233-41.
23. Fan VS, Ramsey SD, Giardino ND, Make BJ, Emery CF, Diaz PT, et al. National Emphysema Treatment Trial (NETT) Research Group. Sex, depression, and risk of hospitalization and mortality in chronic obstructive pulmonary disease. Archives Internal Medicine 2007;167(21):2345-53.
24. Felker B, Bush KR, Harel O, Shofer JB, Shores MM, Au DH. Added burden of mental disorders on health status among patients with chronic obstructive pulmonary disease. Primary Care Companion to the Journal of Clinical Psychiatry 2010;12(4):pii: PCC.09m00858. [DOI: 10.4088/PCC.09m00858gry]
25. Fleehart S, Fan VS, Nguyen HQ, Lee J, Kohen R, Herting JR, et al. Prevalence and correlates of suicide ideation in patients with COPD: a mixed methods study. International Journal of Chronic Obstructive Pulmonary Disease 2014;10:1321-9.
26. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease. Available from: goldcopd.org/uploads/users/files/GOLDReport_April112011.pdf (accessed 05 September 2011) Updated 2010:1-117.
27. Goodwin RD, Lavoie KL, Lemeshow AR, Jenkins E, Brown ES, Fedoronko DA. Depression, anxiety and COPD: the unexamined role of nicotine dependence. Nicotine and Tobacco Research 2012;14(2):176-83.
28. GRADE Working Group. GRADEpro GDT: GRADEpro Guideline Development Tool [Software]. Available from gradepro.org. Version (accessed August 2016). Hamilton ON: McMaster University, (developed by Evidence Prime, Inc.), 2015.
29. Groenewegen KH, Schols AM, Wouters EF. Mortality and mortality-related factors after hospitalization for acute exacerbation of COPD. Chest 2003;124(2):459-67.
30. Gudmundsson G, Gislason T, Janson C, Lindberg E, Hallin R, Ulrik CS, et al. Risk factors for rehospitalisation in COPD: role of health status, anxiety and depression. European Respiratory Journal 2005;26(3):414-9.
31. Hamilton M. A rating scale for depression. Journal of Neurology, Neurosurgery and Psychiatry 1960;23:56-62.
32. Hanania NA, Müllerova H, Locantore NW, Vestbo J, Watkins ML, Wouters EF, et al. the Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) study investigators. Determinants of depression in the ECLIPSE chronic obstructive pulmonary disease cohort. American Journal of Respiratory and Critical Care Medicine 2011;183:604-11.
33. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration. Available from handbook.cochrane.org.
34. Hisaoka-Nakashima K, Miyano K, Matsumoto C, Kajitani N, Abe H, Okada-Tsuchioka M, et al. Tricyclic antidepressant amitriptyline-induced glial cell line-derived neurotrophic factor production involves pertussis toxin-sensitive gαi/o activation in astroglial cells. The Journal of Biological Chemistry 2015;290(22):13678-91.
35. Hutter N, Schnurr A, Baumeister H. Health care costs in patients with diabetes mellitus and comorbid mental disorders - a systematic review. Diabetologia 2010;53(12):2470-9.
36. Jones PW, Quirk FH, Baveystock CM. The St George's Respiratory Questionnaire. Respiratory Medicine 1991;85(Suppl B):25-31.
37. Sadock BJ, Sadock VA, Ruiz P. Kaplan and Sadock's Comprehensive Textbook of Psychiatry. 9th Edition. Philadelphia, London: Wolters Kluwer Health/Lippincott Williams & Wilkins, 2009.
38. Karajgi B, Rifkin A, Doddi S, Kolli R. The prevalence of anxiety disorders in patients with chronic obstructive pulmonary disease. American Journal of Psychiatry 1990;147:200-1.
39. Kim HF, Kunik ME, Molinari VA, Hillman SL, Lalani S, Orengo CA, et al. Functional impairment in COPD patients: the impact of anxiety and depression. Psychosomatics 2000;41(6):465-71.
40. Kim KU, Park HK, Jung HY, Ahn JJ, Moon E, Kim YS, et al. Association of depression with disease severity in patients with chronic obstructive pulmonary disease. Lung 2014;192:243-9.
41. Kunik ME, Roundy K, Veazey C, Souchek J, Richardson P, Wray NP, et al. Surprisingly high prevalence of anxiety and depression in chronic breathing disorders. Chest 2005;127(4):1205-11.
42. Lacasse Y, Beaudoin L, Rousseau L, Maltais F. Randomized trial of paroxetine in end-stage COPD. Monaldi Archives of Chest Disease 2004;61(3):140-7.
43. Lopez AD, Shibuya K, Rao C, Mathers CD, Hansell AL, Held LS, et al. Chronic obstructive pulmonary disease: current burden and future projections. European Respiratory Journal 2006;27(2):397-412.
44. Lovibond SH, Lovibond PF. Manual for Depression Anxiety Stress Scales. 2nd Edition. Sydney: The Psychology Foundation, University of New South Wales, 1995.
45. Maurer J, Rebbapragada V, Borson S, Goldstein R, Kunik ME, Yohannes AM, et al. Anxiety and depression in COPD: current understanding, unanswered questions, and research needs. Chest October 2008;134:43S-53S.
46. Naylor C, Parsonage M, McDaid D, Knapp M, Fossey M, Galea A, The Kings Fund and Centre for Mental Health. Long-term conditions and mental health. The cost of co-morbidities. Available from kingsfund.org.uk/publications/long-term-conditions-and-mental-health 2012:1-32.
47. Ng TP, Niti M, Tan WC, Cao Z, Ong KC, Eng P. Depressive symptoms and chronic obstructive pulmonary disease: effect on mortality, hospital readmission, symptom burden, functional status, and quality of life. Archives of Internal Medicine 2007;167(1):60-7.
48. National Collaborating Centre for Mental Health (UK). Depression: The treatment and management of depression in adults (updated edition). The British Psychological Society; National Institute for Health and Clinical Excellence Guidelines UK, 2010.
49. Omachi TA, Katz PP, Yelin EH, Gregorich SE, Iribarren C, Blanc PD, et al. Depression and health-related quality of life in chronic obstructive pulmonary disease. American Journal of Medicine 2009;122(8):778.e9-15.
50. Panagioti M, Scott C, Blakemore A, Coventry PA. Overview of the prevalence, impact, and management of depression and anxiety in chronic obstructive pulmonary disease. International Journal of COPD 2014;9:1289-306.
51. Pignone MP, Gaynes BN, Rushton JL, Burchell CM, Orleans CT, Murlow CD, et al. Screening for depression in adults: a summary of the evidence for the U.S. Preventive Services Task Force. Annals of Internal Medicine 2002;136(10):765-76.
52. Pumar MI, Gray CR, Walsh JR, Yang IA, Rolls TA, Ward DL. Anxiety and depression - important psychological comorbidities of COPD. Journal of Thoracic Disease 2014;6(11):1615-31.
53. Rabe KF, Hurd S, Anzueto A, Barnes PJ, Buist SA, Calverley P, et al. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. American Journal of Respiratory and Critical Care Medicine 2007;176(6):532-5.
54. Rajkowska G, Stockmeier CA. Astrocyte pathology in major depressive disorder: insights from human postmortem brain tissue. Current Drug Targets 2013;14(11):1225-36.
55. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014.
56. Schatzberg AF, Rothschild AJ. Serotonin activity in psychotic (delusional) major depression. Journal of Clinical Psychiatry 1992;53:52-5.
57. Skaer TL, Sclar DA, Robison LM. Trends in prescriptions for antidepressant pharmacotherapy among US children and adolescents diagnosed with depression, 1990 through 2001: an assessment of accordance with treatment recommendations from the American Academy of Child and Adolescent Psychiatry. Clinical Therapeutics 2009;31:1478-87.
58. Smith SM, Sonego S, Ketcheson L, Larson JL. A review of the effectiveness of psychological interventions used for anxiety and depression in chronic obstructive pulmonary disease. BMJ Open Respiratory Research 2014;1:1-10.
59. Spitzer RL, Kroenke K, Williams JBW. Patient Health Questionnaire Study Group. Validity and utility of a self-report version of PRIME-MD: the PHQ Primary Care Study. JAMA 1999;282:1737-44.
60. Usmani ZA, Carson KV, Cheng JN, Esterman AJ, Smith BJ. Pharmacological interventions for the treatment of anxiety disorders in chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews 2011, Issue 11. [DOI: 10.1002/14651858.CD008483.pub2]
61. Usmani ZA, Carson KV, Heslop K, Esterman AJ, De Soyza A, Smith BJ. Psychological therapies for the treatment of anxiety disorders in chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews 2013, Issue 7. [DOI: 10.1002/14651858.CD010673]
62. van Manen JG, Bindels PJ, Dekker FW, IJzermans CJ, van der Zee JS, Schadé E. Risk of depression in patients with chronic obstructive pulmonary disease and its determinants. Thorax 2002;57(5):412-6.
63. Ware JE, Snow KK, Kosinski M, Gandek B. SF-36 Health Survey: manual and interpretation guide. Boston MA: Health Institute, New England Medical Center, 1993.
64. World Health Organization. COPD predicted to be the third leading cause of death in 2030. Available from who.int/respiratory/copd/World_Health_Statistics_2008/en 2008.
65. Wittchen HU, Jacobi F, Rehm J, Gustavsson A, Svensson M, Jönsson B, et al. The size and burden of mental disorders and other disorders of the brain in Europe 2010. European Neuropsychopharmacology 2011;21(9):655-79.
66. Yohannes AM, Baldwin RC, Connolly MJ. Predictors of 1-year mortality in patients discharged from hospital following acute exacerbation of chronic obstructive pulmonary disease. Age and Ageing 2005;34:491-6.
67. Yohannes AM. Management of anxiety and depression in patients with COPD. Expert Review of Respiratory Medicine 2008;2(3):337-47.
68. Zhang MW, Ho RC, Cheung MW, Fu E, Mak A. Prevalence of depressive symptoms in patients with chronic obstructive pulmonary disease: a systematic review, meta-analysis and meta-regression. General Hospital Psychiatry Journal 2011;33(3):217-23.